Who We Are

Trobix Bio is an Israeli biotech company pioneering the field of human microbiome via its TBX™ technology platform, utilizing CRISPR, phage and synthetic biology to re-program specific activities in targeted microbiome bacteria and develop orally administered precision oncology therapeutics.

Targeting cumulative markets of over $4 billion, Trobix’s preclinical products, TBX201 and TBX301, are being developed to reduce severe diarrhea and colitis in patients receiving irinotecan or checkpoint inhibitors, respectively. Our products may allow physicians to complete more oncology treatments and improve cancer patients’ quality of life.

What Makes Us Unique

  • CRISPR-Cas3 drives in-vivo selection of TBX Cargo to generate a robust and durable therapeutic effect

    CRISPR-Cas3 drives in-vivo selection of TBX Cargo to generate a robust and durable therapeutic effect

  • Manipulating specific activities in targeted microbiome bacteria

    Manipulating specific activities in targeted microbiome bacteria

  • Oral delivery of human biotherapeutics

    Oral delivery of human biotherapeutics

  • Precise targeting with no disruption of the natural microbiome

    Precise targeting with no disruption of the natural microbiome

  • Innovative unified core system for phage cocktail production

    Innovative unified core system for phage cocktail production